{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=INCB039110", "query": { "intervention": "INCB039110" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 42, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=INCB039110&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T00:43:44.196Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01634087", "title": "A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plaque Psoriasis" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 50, "start_date": "2012-06", "completion_date": "2013-02", "has_results": false, "last_update_posted_date": "2019-03-12", "last_synced_at": "2026-09-05T00:43:44.196Z", "location_count": 5, "location_summary": "Hot Springs, Arkansas • Los Angeles, California • Clinton, Minnesota + 2 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Clinton", "state": "Minnesota" }, { "city": "Fridley", "state": "Minnesota" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01634087" }, { "nct_id": "NCT04239989", "title": "Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bronchiolitis Obliterans" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Itacitinib Adipate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 8, "start_date": "2021-10-08", "completion_date": "2025-10-31", "has_results": false, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-09-05T00:43:44.196Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04239989" }, { "nct_id": "NCT01858883", "title": "Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors", "Pancreatic Cancer" ], "interventions": [ { "name": "itacitinib", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2013-06", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2019-07-18", "last_synced_at": "2026-09-05T00:43:44.196Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Southington", "state": "Connecticut" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01858883" }, { "nct_id": "NCT04859946", "title": "Itacitinib for the Prevention of Graft Versus Host Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic and Lymphocytic Disorder" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Itacitinib", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 31, "start_date": "2022-01-11", "completion_date": "2027-04-01", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-09-05T00:43:44.196Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04859946" }, { "nct_id": "NCT04629508", "title": "To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis", "Polycythemia Vera", "Thrombocythemia" ], "interventions": [ { "name": "itacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2021-07-12", "completion_date": "2023-08-24", "has_results": true, "last_update_posted_date": "2025-09-02", "last_synced_at": "2026-09-05T00:43:44.196Z", "location_count": 8, "location_summary": "New Orleans, Louisiana • Bethesda, Maryland • Kansas City, Missouri + 5 more", "locations": [ { "city": "New Orleans", "state": "Louisiana" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Brick", "state": "New Jersey" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04629508" }, { "nct_id": "NCT04061421", "title": "Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "MDS/MPN" ], "interventions": [ { "name": "ASTX727", "type": "DRUG" }, { "name": "Itacitinib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael Savona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2021-11-24", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-09-05T00:43:44.196Z", "location_count": 4, "location_summary": "Tampa, Florida • Rochester, New York • Portland, Oregon + 1 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Rochester", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04061421" }, { "nct_id": "NCT02760485", "title": "A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "itacitinib", "type": "DRUG" }, { "name": "ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2016-12-29", "completion_date": "2022-06-06", "has_results": true, "last_update_posted_date": "2023-06-15", "last_synced_at": "2026-09-05T00:43:44.196Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • Duarte, California • Long Beach, California + 18 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02760485" }, { "nct_id": "NCT04446182", "title": "Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Graft-versus-host-disease" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Extracorporeal Photopheresis (ECP)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2021-01-29", "completion_date": "2023-01-30", "has_results": true, "last_update_posted_date": "2024-01-22", "last_synced_at": "2026-09-05T00:43:44.196Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04446182" }, { "nct_id": "NCT03846479", "title": "Itacitinib for Low Risk GVHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Low Risk Acute Graft-versus-host Disease", "Graft-versus-host-disease", "GVHD" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John Levine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 70, "start_date": "2019-03-25", "completion_date": "2022-05-11", "has_results": true, "last_update_posted_date": "2023-02-06", "last_synced_at": "2026-09-05T00:43:44.196Z", "location_count": 14, "location_summary": "Duarte, California • Los Angeles, California • Atlanta, Georgia + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03846479" }, { "nct_id": "NCT02355431", "title": "Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors and Hematologic Malignancy", "NSCLC (Non-small Cell Lung Carcinoma)" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "erlotinib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-12", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2019-03-08", "last_synced_at": "2026-09-05T00:43:44.196Z", "location_count": 1, "location_summary": "Ogden, Utah", "locations": [ { "city": "Ogden", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02355431" } ] }